Adagrasib vs Glecirasib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Adagrasib · Krazati

Marketed by Bristol-Myers Squibb and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04685135 · Phase 3 · active, not recruiting

This was a randomized phase 3 trial of 453 people against an active comparator (docetaxel). The progression-free survival endpoint, reviewed by a blinded independent committee, was clearly met, but treatment was open-label, so it is graded below the highest tier.

Next expected readout: January 2027 · NCT06026410 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) as Per Blinded Independent Central Review (From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)): Progression-Free Survival (PFS) as Per Blinded Independent Central Review (From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)): Adagrasib 5.49 months (95% CI 4.53 to 6.67) | Docetaxel 3.84 months (95% CI 2.73 to 4.73) (met)

Result source: NCT04685135

Glecirasib

Marketed by Allist Pharmaceuticals under a licence from Jacobio Pharmaceuticals

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05002270 · Phase 1/2 · completed

The study was a small, non-randomized, open-label trial without a comparator, evaluating safety, tumor response, and duration of response. Because results are not posted and the design cannot provide a controlled comparison, it offers limited evidence for glecirasib.

Next expected readout: March 2027 · NCT05288205 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAdagrasibGlecirasib
PFS, median—Trial running · NCT04613596—Trial running · NCT07601048
OS, median—Trial running · NCT04613596—Trial running · NCT07601048
ORR—Trial running · NCT04613596—Trial running · NCT07601048
Duration of response, median—Trial running · NCT04613596—Trial running · NCT07601048

PFS, median

Adagrasib
—Trial running · NCT04613596
Glecirasib
—Trial running · NCT07601048

OS, median

Adagrasib
—Trial running · NCT04613596
Glecirasib
—Trial running · NCT07601048

ORR

Adagrasib
—Trial running · NCT04613596
Glecirasib
—Trial running · NCT07601048

Duration of response, median

Adagrasib
—Trial running · NCT04613596
Glecirasib
—Trial running · NCT07601048
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Adagrasib: registry results are on file for Non-Small Cell Lung Cancer, but their comparison mappings are not yet available.

Glecirasib: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Adagrasib's landscape · Glecirasib's landscape